- Home
- TNGX vs BRSP Comparison
TNGX vs BRSP Comparison
Compare TNGX & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- BRSP
- Stock Information
- Founded
- TNGX 2014
- BRSP 2017
- Country
- TNGX United States
- BRSP United States
- Employees
- TNGX N/A
- BRSP N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- BRSP Real Estate Investment Trusts
- Sector
- TNGX Health Care
- BRSP Real Estate
- Exchange
- TNGX Nasdaq
- BRSP Nasdaq
- Market Cap
- TNGX 723.2M
- BRSP 665.4M
- IPO Year
- TNGX N/A
- BRSP 2018
- Fundamental
- Price
- TNGX $6.90
- BRSP $5.78
- Analyst Decision
- TNGX Strong Buy
- BRSP Buy
- Analyst Count
- TNGX 6
- BRSP 4
- Target Price
- TNGX $10.00
- BRSP $6.38
- AVG Volume (30 Days)
- TNGX 1.9M
- BRSP 788.9K
- Earning Date
- TNGX 08-05-2025
- BRSP 07-29-2025
- Dividend Yield
- TNGX N/A
- BRSP 11.07%
- EPS Growth
- TNGX N/A
- BRSP N/A
- EPS
- TNGX N/A
- BRSP N/A
- Revenue
- TNGX $24,296,000.00
- BRSP $335,107,000.00
- Revenue This Year
- TNGX N/A
- BRSP N/A
- Revenue Next Year
- TNGX N/A
- BRSP $9.97
- P/E Ratio
- TNGX N/A
- BRSP N/A
- Revenue Growth
- TNGX N/A
- BRSP N/A
- 52 Week Low
- TNGX $1.03
- BRSP $4.16
- 52 Week High
- TNGX $12.02
- BRSP $6.45
- Technical
- Relative Strength Index (RSI)
- TNGX 56.63
- BRSP 68.65
- Support Level
- TNGX $6.60
- BRSP $5.49
- Resistance Level
- TNGX $7.42
- BRSP $5.69
- Average True Range (ATR)
- TNGX 0.47
- BRSP 0.13
- MACD
- TNGX -0.04
- BRSP 0.03
- Stochastic Oscillator
- TNGX 57.20
- BRSP 96.51
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.